Lutetium (177Lu) NeoB

DB30389InvestigationalProtein Based Therapies

Lutetium (177Lu) NeoB is a biologic drug. Lutetium (177Lu) NeoB is under investigation in clinical trial NCT06379217 (NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR...

Mechanism: Pharmacologically active on Gastrin-releasing peptide receptor
Curator reviewed
Also known as: [177Lu]Lu-NeoB · Lu-NeoB · lutetium neoB
Code names: AAA603

Resolves to

Targets

P30550GRPR

What you can answer from here — as of April 27, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Lutetium (177Lu) NeoB, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account